====== Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available ====== **Objective:** Derive data that large healthcare organizations can combine data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. **Project Lead(s):** Richard D. Boyce, Matthias Samwald, Patrick Ryan, (seeking other collaborators) **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna ** Additional Participants:** //// **Full Protocol:** //// **Initial Proposal Date:** 2/16/2015 **Launch Date:** //// **Study Closure Date: ////** **Results Submission:** //// ===== Requirements ===== **CDM:** V4 or V5 **Table Accessed:** DRUG_EXPOSURE, CONCEPT_ANCESTOR, CONCEPT_RELATIONSHIP, PERSON **Database Dialects:** SQL Server, Postgres, Oracle **Software:** SQL and R ===== Code ===== [[https://github.com/OHDSI/StudyProtocols/tree/master/Proposed%20Study%203%20-%20Incidence%20of%20exposure%20to%20PGx%20drugs|GitHub code for Proposed Study 3 - Incidence of exposure to PGx drugs]] ===== Discussion ===== //Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// ===== Datasets Run ===== * Truven CCAE in the IMEDS lab * Truven MDCD in the IMEDS lab * Truven MDCR in the IMEDS lab ~~NOTOC~~